Amgen (AMGN) announced that its cardiovascular collaborator Servier has exercised its option to commercialize omecamtiv mecarbil for the treatment of chronic heart failure in Europe and the Commonwealth of Independent States, including Russia. In addition, the Phase 3 development program will move forward in collaboration with omecamtiv mecarbil discoverer Cytokinetics (CYTK). According to the terms of the agreement, Servier will make a $10M option exercise payment to Amgen, in addition to future milestones and royalties. Development costs will be shared. Amgen and Cytokinetics initiated their strategic alliance to develop cardiac myosin activators in January 2007.